Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, Inc. (AMRS) reported a strong Q3 2022, showcasing a core revenue of $71.1 million, up 49% year-over-year, fueled by record consumer revenue of $46.6 million—a 98% increase. The company successfully implemented its 'Fit to Win' initiatives, generating $10 million in earnings improvements. New funding of $180 million supports ongoing growth. Despite a GAAP net loss of $161.4 million and increased operating expenses, Amyris aims to maintain momentum heading into 2023, projecting core revenue to exceed $100 million in Q4.
Amyris, Inc. (Nasdaq: AMRS), a synthetic biotechnology company, will report its financial results for Q3 2022 on November 8, 2022, after market close. A conference call will follow at 1:30 PM PT, featuring CEO John Melo and CFO Han Kieftenbeld, discussing results and business updates. Amyris focuses on sustainable ingredients for Clean Health & Beauty and Flavors & Fragrances, leveraging its Lab-to-Market technology platform, which integrates machine learning and AI for rapid innovation, reaching over 300 million consumers through more than 20,000 products from top brands.
Amyris, a synthetic biotechnology company, has announced a partnership with the World Wildlife Fund (WWF) to enhance ocean health and reduce the impact of fishing on shark populations. The collaboration aligns with Amyris' commitment to Environmental, Social, and Governance (ESG) goals, as highlighted in its 2021 ESG report. The partnership aims to promote sustainable fishing practices in Ecuador and Peru and will explore eco-friendly ingredients to mitigate ocean ecosystem impacts. This initiative underscores the need for corporate responsibility in biodiversity conservation.
Amyris, Inc. (Nasdaq: AMRS) announced the launch of two new consumer brands: Stripes™ for (peri)menopausal wellness and EcoFabulous™ for Gen-Z beauty. Stripes launched on October 18, 2022, while EcoFabulous debuted on October 20, 2022. Both brands will be available on Amazon in November and in retail stores soon. CEO John Melo reported strong consumer demand and expects a strong end to 2022, continuing to expand Amyris' portfolio, which includes popular brands like Biossance and Pipette.
Amyris, Inc. (Nasdaq: AMRS) announced the inclusion of its brands—Biossance, JVN Hair, and Rose Inc—in Sephora's UK launch on October 17, 2022. This move marks a significant expansion in the UK and is part of a global partnership with Sephora. With ongoing consumer demand for clean beauty products, Amyris has been recognized by Women's Wear Daily as a leading small cap beauty company. The company aims to bolster its offerings and retail presence in the UK and Europe while focusing on operational excellence and reduced costs.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology focused on sustainable consumer products, announced its participation in two investor conferences. The company will engage in fireside chats moderated by equity research analysts, providing updates on its operations. Key events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 7:00 AM ET (virtual) and the Piper Sandler Growth Frontiers Conference on September 13 at 3:30 PM CT (in-person, Nashville, TN). Live webcasts and replays of these presentations will be available on Amyris' Investor Relations website.
Summary not available.
Amyris reported Q2 2022 core revenue of $65.2 million, a 54% increase year-over-year, fueled by record consumer revenue of $43 million, up 108%. Year-to-date, consumer revenue surged 113%. The company anticipates $50 million in EBITDA improvements for H2 2022 due to cost actions and price increases. A substantial $700 million in funding enhances liquidity for ongoing growth. However, cash operating expenses rose 73.7 million from Q2 2021, leading to a GAAP net loss of $110 million. The firm continues to expand its retail presence globally.
Amyris, a synthetic biotechnology leader, announced its participation in the UBS Genomics 2.0 and MedTech Innovations Summit on August 10, 2022, at 3:00 PM PT in Dana Point, CA. Chief Science Officer Sunil Chandran will represent the company during a fireside chat. Amyris focuses on sustainable consumption through its Lab-to-Market™ technology, which employs AI and robotics to scale innovation. The company provides sustainable ingredients used in over 20,000 products globally, reaching more than 300 million consumers.
Amyris, Inc. (Nasdaq: AMRS) announced its financial results for Q2 2022 will be shared on August 9, 2022, before market open. A conference call will follow at 6:00 a.m. PT to discuss these results and provide a business update by CEO John Melo and CFO Han Kieftenbeld. Amyris specializes in sustainable ingredients for Clean Health & Beauty and Flavors & Fragrances markets via its proprietary Lab-to-Market™ platform, reaching over 300 million consumers through 20,000 products.